Last checked at 17 Dec 2023 15:16
PRESS: GSK looks for deals in China as rebuilds relationship
(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,733.50
Bid:
1,732.50
Ask:
1,733.00
Change:
0.00 (0.00%)
Spread:
0.50 (0.029%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
1,733.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Qualye Munro director buys 3.3 per cent stake ahead of de-listing
Tue, 16th Jul 2013 16:14
Glen Lewy, a Non-Executive Director of corporate financial advisory firm Qualye Munro bought a big stake in the company ahead of its proposed de-listing from AIM.Qualye Munro, which first debuted on the London Stock Exchange in 1993, set out proposals last week to cancel the trading of its shares on AIM in conjunction with a tender offer and the adoption of new management incentivisation arrangements. The company, whose 400 shareholders are mainly small private investors, pointed out that the average number of trades per day in the company over the last year was just 0.5 and there is little liquidity in the stock.The firm said that the costs of maintaining an AIM listing are £140,000 annually and a lot of management time is being taken up by "publicly quoted company matters" such as the production of lengthy financial reports.Meanwhile, it believes that a new proposed incentive plan for senior management - which involves them purchasing shares in the business - is not practicable within a publicly quoted firm.In connection with the proposals, Lewy purchased 150,000 shares in the firm at a price of 563p each from the firm's employee benefit trust (EBT), East of Scotland Investments. The £844,500 transaction gave him a 3.29% stake in the company, reducing the EBT's interest to just 0.35%.Qualye Munro said the shares purchase by Lewy were part of the shares owned by the EBT which gave an irrevocable undertaking to vote in favour of all the resolutions announced last week and not to sell the shares in the tender offer."Lewy intends to vote the acquired shares in favour of all of the resolutions to be proposed at the company's general meeting on August 1st 2013 and does not intend to tender the shares in the tender offer," the firm said.Top Director BuysQuayle Munro Holdings (QYM) Director name: Mr Glen LewyAmount purchased: 150,000 @ 563.00p Value: £844,500GlaxoSmithKline (GSK) Director name: Dr Moncef SlaouiAmount purchased: 1,222 @ 1,721.99p Value: £21,043GlaxoSmithKline (GSK) Director name: Sir Sir Andrew P WittyAmount purchased: 1,238 @ 1,753.00p Value: £21,702Oxford Biomedica (OXB) Director name: Mr Martin Diggle Amount purchased: 1,000,000 @ 1.50p Value: £15,000Matchtech Group (MTEC) Director name: Mr Adrian GunnAmount purchased: 3,494 @ 341.00p Value: £11,915BC
More News
15 Dec 2023 17:08
European shares end fifth week higher on rate-cut optimism
Barclays sees first ECB rate cut in April
*Read more15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:22
TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine
(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more12 Dec 2023 07:24
GSK seeks to extend RSV vaccine approval in Japan
(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.
Read more11 Dec 2023 08:28
GSK drug gets EU marketing backing for form of endometrial cancer
(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.
Read more11 Dec 2023 07:41
LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook
(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.
Read more11 Dec 2023 07:23
GSK endometrial cancer treatment gets Europe authorisation
(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.
Read more7 Dec 2023 12:54
THG backer Kelso pushes for demerger to trim "inherent" valuation gap
(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.
Read more5 Dec 2023 10:02
LONDON BROKER RATINGS: Goldman lifts Landsec and British Land
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more27 Nov 2023 09:00
GSK announces positive results from Blenrep phase 3 blood cancer trial
(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.
Read more27 Nov 2023 08:02
GSK receives 'positive' headline results from phase III trial
(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.
Read more